FGL1 and hepatocellular carcinoma: these were consistent with our research.[18] SERPINF2, also known as α2-antiplasmin, is a gene encoding plasmin inhibitors that can degrade plasma fibrin and other proteins.[19,20] Plasma SerpinF2 is mainly produced in the liver and kidneys and is reduced in patients with nephrotic syndrome.[21] Chen et al showed that compared with nontumor liver, FGG, FGL1, SERPINF2, and MT1G were downregulation in HCC.